Opinion|Videos|November 15, 2024
Unmet Needs for Transplant-Eligible NDMM
Key Takeaways
- Pharmacists can enhance medication adherence and manage side effects, crucial for optimizing multiple myeloma therapy.
- Personalized treatment plans should consider patient-specific factors, including comorbidities and genetic profiles.
Panelists discuss how pharmacists can address remaining unmet needs and challenges in optimizing frontline therapy for patients with transplant-eligible newly diagnosed multiple myeloma (NDMM), including areas such as managing complex drug interactions, improving medication adherence, mitigating treatment-related toxicities, streamlining transitions of care, and enhancing patient education and support throughout the treatment journey.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are remaining unmet needs or challenges you see around optimizing frontline therapy for patients with transplant-eligible newly diagnosed multiple myeloma that pharmacists can address?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Obinutuzumab-Bendamustine Produces High Response Rates in Chinese Patients With Indolent B-Cell Lymphomas
2
State Pharmacy Boards Must Step Up Against Illegal Retatrutide
3
New CKD Outcome Set Tells Pharmacists What to Measure
4
GLP-1s and the HCM–Sleep Apnea–Obesity Connection
5